Sarilumab is effective rapidly in ultrasound for patients with rheumatoid arthritis
2019 Volume 31 Issue 1 Pages 41-47
Details
2019 Volume 31 Issue 1 Pages 41-47
Objective: The purpose of this study was to examine short-term efficacy of sarilumab therapy in patients with rheumatoid arthritis（RA）.
Subjects and methods: Five patients with RA who underwent sarilumab treatment were assessed. 200 mg of sarilumab was administered SC by subcutaneous injection every 2 weeks for 12 weeks to patients with RA. Disease activity of RA was examined by DAS28-ESR and ultrasonography.
Results: All patients were women（mean age 64.0 ± 17.8, mean disease duration 16.5 ± 14.0 years）. DAS28-ESR was significantly improved（4.58 ± 0.65 at baseline to 2.90 ± 0.76 at 12 weeks p= 0.03）. Total power Doppler score was also significantly improved（10.6 ± 2.2 at baseline to 2.0 ± 1.9 at 12 weeks p= 0.0067）.
Conclusions: These findings suggested that sarilumab may lead to rapid improvement assessed by DAS28-ESR and ultrasound in patients with rheumatoid arthritis.
